Butrynski and colleagues were one of the first to report a sustained partial response to crizotinib in a patient with ALK-rearranged IMT and mechanistically compared it with the absence of activity of crizotinib in another patient with IMT without ALK rearrangement79. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.